Merit Medical Systems Inc. (MMSI) 12-Month Stock Forecast & Price Target Cone

MMSI scores 75 out of 100, graded B and labeled "Roarable Buy — Good Risk/Reward." The score is built from five pillars:

• Fundamental Cash Engine (15 / 20): this pillar reflects ROIC of 7.8% and an FCF yield of 3.87%. For a prospective investor, this suggests the business generates cash at a moderate rate relative to its market value, though not at a level that would by itself make the stock look inexpensive.
• Whale 13F Flow (17 / 20): The highest pillar, described in the rating as reflecting institutional accumulation and options positioning. The underlying holder data is not itemized in the source data, so the investor should treat this as a summary score rather than a verified ownership picture.
• Insider Conviction (12 / 20): this reflects SEC Form 4 and Congressional PTR cluster flow.
• Macro Regime Fit (13 / 20): beta is 0.94 and sector sensitivity is reflected in this score. A beta near 1.0 implies the stock has moved roughly in line with the broader market, so it is not positioned as a low-volatility or high-volatility outlier on this measure.
• Forensic Balance Sheet (18 / 20): The strongest pillar, citing Altman Z 4.62, Piotroski F 9/9, and Debt/Equity 0.46 per the rating. These readings point to balance-sheet strength by the rating's measures.

Valuation tradeoff: the market data shows P/E (TTM) of 43.4 and forward P/E of 40.4. Strong balance-sheet and institutional pillars coexist with a demanding earnings multiple, so the rating's upside case depends on continued earnings growth to justify the price. This is an analytical observation, not a recommendation.

Merit Medical Systems Inc. Is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry. Specific product lines, customer segments, and revenue-generation mechanics are — The profile section confirms only sector, industry, exchange, and market capitalization of $5.6B.

Revenue, operating income, net income, and free cash flow rose across the three reported fiscal years. Current market data shows gross margin of 48.7%, operating margin of 12.2%, and net margin of 8.5%, with ROIC of 7.8%. The Altman Z-Score is 4.62 and the Piotroski F-Score is 9/9, with Debt/Equity of 0.46. Debt in the financials rose modestly across the period while cash also increased; FY 2023 cash is —

• 🐂 Primary Bull Case: The Forensic Balance Sheet pillar scores 18/20 on Altman Z 4.62, Piotroski F 9/9, and Debt/Equity 0.46. With Fundamental Cash Engine at 15/20 (ROIC 7.8%, FCF yield 3.87%) and Institutional Whale Flow at 11/20, sustained execution supports upside toward the top of the $59.74 – $94.85 52-week range.
• 🐻 Primary Bear Case: At a P/E (TTM) of 43.4 and ROIC of 7.8%, the stock prices in substantial future earnings growth relative to its current returns. Investors must weigh 43.4x trailing P/E and 23.1x EV/EBITDA against 12.2% operating margins and a 0.94 macro beta if sector demand softens.

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be assessed from the provided sources.

• Key Question #1: What specific product lines and customer segments drive revenue, and how do they break down?
• Key Question #2: What are the EPS figures for the reported fiscal years, which the financials list as N/A?
• Key Question #3: What is the FY 2023 cash balance, which the financials list as N/A?